Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

Core Points - Keros Therapeutics, Inc. has initiated a cash tender offer to repurchase up to $194.4 million of its common stock at a price of $17.75 per share as part of a $375 million capital return program [1] - The tender offer is set to expire on November 18, 2025, unless extended or terminated earlier [2] - Keros plans to fund the tender offer using its existing cash and cash equivalents [1] Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional signaling of the TGF-ß protein family [6] - The company is recognized for its understanding of TGF-ß proteins, which regulate the growth and maintenance of various tissues [6] - Keros' lead product candidate, KER-065, targets neuromuscular diseases, particularly Duchenne muscular dystrophy, while its advanced candidate, elritercept, is aimed at treating cytopenias in myelodysplastic syndrome and myelofibrosis patients [6]